Intech Investment Management LLC Purchases Shares of 26,013 Annexon, Inc. (NASDAQ:ANNX)

Intech Investment Management LLC purchased a new stake in shares of Annexon, Inc. (NASDAQ:ANNX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,013 shares of the company’s stock, valued at approximately $154,000.

Other hedge funds have also modified their holdings of the company. Comerica Bank purchased a new stake in shares of Annexon during the first quarter valued at about $72,000. Sandia Investment Management LP purchased a new position in shares of Annexon in the 2nd quarter valued at approximately $49,000. Victory Capital Management Inc. purchased a new position in shares of Annexon in the 2nd quarter valued at approximately $51,000. Principal Financial Group Inc. purchased a new position in shares of Annexon in the 2nd quarter valued at approximately $56,000. Finally, Allegheny Financial Group LTD raised its position in shares of Annexon by 16.1% in the 2nd quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company’s stock valued at $123,000 after purchasing an additional 3,500 shares during the last quarter.

Insiders Place Their Bets

In other Annexon news, EVP Ted Yednock sold 5,408 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total transaction of $40,073.28. Following the completion of the transaction, the executive vice president now directly owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. This trade represents a 7.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 12.67% of the stock is currently owned by insiders.

Annexon Trading Up 0.6 %

ANNX opened at $5.10 on Friday. Annexon, Inc. has a 12-month low of $2.27 and a 12-month high of $8.40. The firm has a market capitalization of $543.61 million, a PE ratio of -4.86 and a beta of 1.10. The firm has a 50 day moving average of $6.50 and a two-hundred day moving average of $5.98.

Analyst Ratings Changes

ANNX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.